Literature DB >> 11329541

Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation.

Y Ohta1, T Shimada, H Yoshitomi, S Inoue, Y Murakami, H Shimizu, K Nakamura, T Ohta, H Katoh, Y Ishibashi.   

Abstract

BACKGROUND: According to previous reports, plasma atrial natriuretic peptide levels increase in atrial fibrillation (AF) and decrease after successful direct current (DC) cardioversion, but there have been no reports on plasma brain natriuretic peptide (BNP).
OBJECTIVE: To determine whether plasma BNP levels decrease after successful direct DC cardioversion in patients with chronic AF. PATIENTS AND METHODS: Twenty patients who remained in sinus rhythm for at least seven days after cardioversion, and 20 normal control subjects, were studied. Group A consisted of 10 patients with underlying heart disease, including dilated cardiomyopathy (n=2), hypertrophic cardiomyopathy (n=1), mitral valve disease (n=3), hypertensive heart disease (n=3) and status after atrial septal closure (n=1). Group B consisted of 10 patients with just AF. Group C (serving as controls) comprised 20 subjects with normal sinus rhythm and no risk factors.
RESULTS: Before cardioversion, plasma BNP levels were higher in group A (176.7+/-128.1 ng/mL) and in group B (96.8+/-51.7 ng/ml) than in group C (6.3+/-3.8 ng/ml) (P<0.01 for all). After successful cardioversion, mean plasma BNP levels in groups A and B decreased from 136.8+/-105.5 ng/mL to 46.4+/-44.2 ng/mL (P<0.01). In group A, plasma BNP levels decreased from 176.7+/-128.1 ng/mL to 62.5+/-54.6 ng/mL (P<0.01), and in group B, plasma BNP levels decreased from 96.8+/-51.7 ng/mL to 30.3+/-23.8 ng/mL (P<0.01).
CONCLUSIONS: Lone AF raises plasma BNP levels, which is more marked if there is underlying structural heart disease present, and cardioversion reduces plasma BNP levels. Therefore, high plasma BNP levels in patients with chronic AF are likely to be caused by AF and reflect cardiac overloading associated with, although contributed to in part by, underlying heart diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329541

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  10 in total

1.  Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin.

Authors:  E Santamarina; A Penalba; T García-Berrocoso; P Delgado; M Quintana; T González-Alujas; M Ribó; O Maisterra; C A Molina; A Evangelista; J Alvarez-Sabín; J Montaner
Journal:  J Neurol       Date:  2012-05-17       Impact factor: 4.849

2.  Correlation between plasma brain natriuretic peptide levels and left atrial appendage flow velocity in patients with non-valvular atrial fibrillation and normal left ventricular systolic function.

Authors:  Masahiko Harada; Satoshi Tabako; Yuichiro Fujii; Yuichi Takarada; Kyoko Hayashi; Hiroshi Ohara; Fumihiko Hara; Takanori Ikeda
Journal:  J Echocardiogr       Date:  2017-12-18

3.  Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.

Authors:  Mehmet Ozaydin; Yasin Turker; Ercan Varol; Sule Alaca; Dogan Erdogan; Nigar Yilmaz; Abdullah Dogan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

4.  Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion.

Authors:  D-I Shin; K Jaekel; Ph Schley; A Sause; M Müller; R Fueth; T Scheffold; H Guelker; M Horlitz
Journal:  Z Kardiol       Date:  2005-12

5.  Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation.

Authors:  T Date; T Yamane; K Inada; S Matsuo; S Miyanaga; K Sugimoto; K Shibayama; I Taniguchi; S Mochizuki
Journal:  Heart       Date:  2006-06-01       Impact factor: 5.994

6.  Elevated brain natriuretic peptide level in patients undergoing atrial fibrillation ablation: is it a predictor of failed ablation or a mere function of atrial rhythm and rate at a point in time?

Authors:  Jayasree Pillarisetti; Namratha Reddy; Mazda Biria; Kay Ryschon; Darbhamulla Nagarajan; Caroline Murray; Donita Atkins; Sudharani Bommana; Madhu Yeruva Reddy; Luigi DiBiase; Rhea Pimentel; Loren Berenbom; Buddhadeb Dawn; Andrea Natale; Dhanunjaya Lakkireddy
Journal:  J Interv Card Electrophysiol       Date:  2014-05-08       Impact factor: 1.900

Review 7.  Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Authors:  Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor
Journal:  Circulation       Date:  2018-09-04       Impact factor: 29.690

8.  Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction.

Authors:  Konstantinos P Letsas; Gerasimos S Filippatos; Loukas K Pappas; Constantinos C Mihas; Virginia Markou; Ioannis P Alexanian; Michalis Efremidis; Antonios Sideris; Alan S Maisel; Fotios Kardaras
Journal:  Clin Res Cardiol       Date:  2008-10-30       Impact factor: 5.460

9.  Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation.

Authors:  David Carballo; Stephane Noble; Sebastian Carballo; Jérome Stirnemann; Hajo Muller; Haran Burri; Nicolas Vuilleumier; Mario Talajic; Jean-Claude Tardif; Pierre-Frederic Keller; Francois Mach; Dipen Shah
Journal:  J Int Med Res       Date:  2018-09-04       Impact factor: 1.671

10.  Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic Peptide plasma levels.

Authors:  Dong-In Shin; Thomas Deneke; Eduard Gorr; Helge Anders; Kathrin Buenz; Marcus Paesler; Marc Horlitz
Journal:  Indian Pacing Electrophysiol J       Date:  2009-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.